Matthias Zipfel

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Cross-sectional increase of adherence to multidisciplinary tumor board decisions

S. Hollunder, Ulrich Herrlinger, Matthias Zipfel et al. · BMC Cancer · 2018 · 64 citations · Full text

Medicine, Oncology, Medical Oncology +13

Lung cancer screening with MRI: results of the first screening round

Michael Meier-Schroers, Rami Homsi, Dirk Skowasch et al. · Journal of Cancer Research and Clinical Oncology · 2017 · 52 citations · Full text

Medicine, Oncology, Radiology +14

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108)

Konrad Klinghammer, Thomas Gauler, Andreas Dietz et al. · European Journal of Cancer · 2019 · 30 citations

Medicine, Oncology, Chemotherapy +9